VEGFA and myocardial infarction: Preventing short-term fatal consequences of hypertension, such as myocardial infarction (MI) and cerebrovascular accident, and maximizing the clinical effect of anti-VEGF medications at therapeutic doses are the aims of antihypertensive therapy in individuals who have advanced malignant cancers with shorter survival expectancy compared with the general population [73].